Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bisoprolol fumarate
Drug ID BADD_D00278
Description Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs.[A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.[A180562]
Indications and Usage For management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
Marketing Status Prescription; Discontinued
ATC Code C07AB07
DrugBank ID DB00612
KEGG ID D00634
MeSH ID D017298
PubChem ID 6917733
TTD Drug ID D0K3ZR
NDC Product Code 61919-787; 52817-270; 63187-871; 68071-5097; 52817-271; 65862-087; 10920-571; 62332-603; 71335-1678; 65862-380; 65862-086; 29300-127; 65085-0051; 70954-455; 50268-127; 53747-009; 66064-1004; 52932-0720; 57451-1192; 62332-604; 38779-3142; 29300-126; 63629-6907; 70954-456; 63629-5173; 68071-1582
Synonyms Bisoprolol | Bisoprolol Fumarate (1:1) Salt, (+-)-Isomer | Bisoprolol Fumarate (2:1) Salt, (+-)-Isomer | Bisoprolol Hydrochloride | Hydrochloride, Bisoprolol | Bisoprolol Methanesulfonate Salt | Bisoprolol, (+-)-Isomer | Bisoprolol, Fumarate (1:1) Salt | Bisoprolol, Fumarate (2:1) Salt | CL-297939 | CL 297939 | CL297939 | Concor | EMD-33512 | EMD 33512 | EMD33512 | Bisoprolol Fumarate | Fumarate, Bisoprolol | Bisoprolol, (-)-Isomer
Chemical Information
Molecular Formula C22H35NO8
CAS Registry Number 104344-23-2
SMILES CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O.C(=CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis11.01.13.004; 22.07.03.006--
Sinusitis11.01.13.005; 22.07.03.007--
Skin irritation23.03.04.009--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Syncope02.01.02.008; 17.02.04.008; 24.06.02.012--
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura01.08.01.003; 23.06.01.007--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Hypoacusis04.02.01.006--
Balance disorder17.02.02.007--Not Available
Blood phosphorus increased13.11.01.016--Not Available
Affect lability19.04.01.001--Not Available
Intraocular pressure test13.07.04.011--Not Available
Erectile dysfunction19.08.04.001; 21.03.01.007--
Oropharyngeal pain07.05.05.004; 22.02.05.022--
The 4th Page    First    Pre   4    Total 4 Pages